{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:20:57Z","timestamp":1783527657058,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-026-06125-0","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:27:11Z","timestamp":1779200831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting type I interferon in lupus panniculitis: a case-based systematic literature review"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2889-366X","authenticated-orcid":false,"given":"Giuseppe A.","family":"Ramirez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Corona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3032-2217","authenticated-orcid":false,"given":"Giovanni","family":"Paolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4310-6951","authenticated-orcid":false,"given":"Giovanni","family":"Benanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4285-5966","authenticated-orcid":false,"given":"Gabriele","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1923-5075","authenticated-orcid":false,"given":"Enrica P.","family":"Bozzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8988-9106","authenticated-orcid":false,"given":"Luca","family":"Moroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9324-3161","authenticated-orcid":false,"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7428-315X","authenticated-orcid":false,"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"6125_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2018.11.022","volume":"132","author":"GA Hile","year":"2020","unstructured":"Hile GA, Gudjonsson JE, Kahlenberg JM (2020) The influence of interferon on healthy and diseased skin. Cytokine 132:154605","journal-title":"Cytokine"},{"issue":"3","key":"6125_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y et al (2020) Trial of Anifrolumab in active Systemic Lupus Erythematosus. N Engl J Med 382(3):211\u201321","journal-title":"N Engl J Med"},{"key":"6125_CR3","doi-asserted-by":"crossref","unstructured":"Tani C, Cardelli C, Zen M et al (2024) Anifrolumab In Refractory Systemic Lupus Erythematosus: A Real-Life, Multicenter Study. J Rheumatol","DOI":"10.3899\/jrheum.2024-0053"},{"issue":"11","key":"6125_CR4","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1177\/09612033241273023","volume":"33","author":"S Flouda","year":"2024","unstructured":"Flouda S, Emmanouilidou E, Karamanakos A et al (2024) Anifrolumab for systemic Lupus erythematosus with multi-refractory skin disease: a case series of 18 patients. Lupus 33(11):1248\u201353","journal-title":"Lupus"},{"key":"6125_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11112904","author":"G Paolino","year":"2023","unstructured":"Paolino G, Ramirez GA, Calabrese C et al (2023) Anifrolumab for moderate and severe muco-cutaneous lupus erythematosus: a monocentric experience and review of the current literature. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines11112904","journal-title":"Biomedicines"},{"issue":"1","key":"6125_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jaad.2023.02.044","volume":"89","author":"F Chasset","year":"2023","unstructured":"Chasset F, Jaume L, Mathian A et al (2023) Rapid efficacy of Anifrolumab in refractory cutaneous Lupus erythematosus. J Am Acad Dermatol 89(1):171\u20133","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"6125_CR7","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.0303-6987.2005.00351.x","volume":"32","author":"C Massone","year":"2005","unstructured":"Massone C, Kodama K, Salmhofer W et al (2005) Lupus erythematosus panniculitis (Lupus profundus): clinical, histopathological, and molecular analysis of nine cases. J Cutan Pathol 32(6):396\u2013404","journal-title":"J Cutan Pathol"},{"issue":"7","key":"6125_CR8","doi-asserted-by":"publisher","first-page":"e505","DOI":"10.1016\/S2665-9913(25)00063-3","volume":"7","author":"L Arnaud","year":"2025","unstructured":"Arnaud L, Ruiz-Irastorza G, Aranow C et al (2025) ERN ReCONNET-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations. Lancet Rheumatol 7(7):e505\u2013e18","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"6125_CR9","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1177\/0961203318777103","volume":"27","author":"MP Petersen","year":"2018","unstructured":"Petersen MP, Moller S, Bygum A, Voss A, Bliddal M (2018) Epidemiology of cutaneous Lupus erythematosus and the associated risk of systemic Lupus erythematosus: a nationwide cohort study in Denmark. Lupus 27(9):1424\u20131430","journal-title":"Lupus"},{"issue":"11","key":"6125_CR10","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1001\/jamadermatol.2020.2797","volume":"156","author":"LK Rangel","year":"2020","unstructured":"Rangel LK, Villa-Ruiz C, Lo K et al (2020) Clinical characteristics of Lupus Erythematosus Panniculitis\/Profundus: a retrospective review of 61 patients. JAMA Dermatol 156(11):1264\u20136","journal-title":"JAMA Dermatol"},{"key":"6125_CR11","doi-asserted-by":"crossref","unstructured":"Le Bellour A, Kanbar Y, Delpuech A et al (2025) Efficacy of anifrolumab in lupus erythematous panniculitis: A retrospective study of 11 patients. J Eur Acad Dermatol Venereol","DOI":"10.1111\/jdv.20853"},{"issue":"30","key":"6125_CR12","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2024.39.e225","volume":"39","author":"IC Benlidayi","year":"2024","unstructured":"Benlidayi IC, Gupta L (2024) CAse-BAsed REview sTandards (CABARET): considerations for authors, reviewers, and editors. J Korean Med Sci 39(30):e225","journal-title":"J Korean Med Sci"},{"key":"6125_CR13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"10","key":"6125_CR14","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1111\/head.12246","volume":"53","author":"JJ Gagnier","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG et al (2013) The CARE guidelines: consensus-based clinical case reporting guideline development. Headache 53(10):1541\u20137","journal-title":"Headache"},{"key":"6125_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jaut.2014.01.021","volume":"48\u201349","author":"A Kuhn","year":"2014","unstructured":"Kuhn A, Landmann A (2014) The classification and diagnosis of Cutaneous Lupus Erythematosus. J Autoimmun 48\u201349:14\u20139","journal-title":"J Autoimmun"},{"issue":"7","key":"6125_CR16","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","volume":"44","author":"DA Isenberg","year":"2005","unstructured":"Isenberg DA, Rahman A, Allen E et al (2005) BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group\u2019s disease activity index for patients with Systemic Lupus Erythematosus. Rheumatology (Oxford) 44(7):902\u20136","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"6125_CR17","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D et al (2019) 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78(9):1151\u20131159","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6125_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.rdc.2009.12.001","volume":"36","author":"RS Klein","year":"2010","unstructured":"Klein RS, Morganroth PA, Werth VP (2010) Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument. Rheum Dis Clin North Am 36(1):33\u201351","journal-title":"Rheum Dis Clin North Am"},{"issue":"2","key":"6125_CR19","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Ibanez D, Urowitz MB (2002) Systemic Lupus Erythematosus disease activity index 2000. J Rheumatol 29(2):288\u2013291","journal-title":"J Rheumatol"},{"issue":"2","key":"6125_CR20","first-page":"373","volume":"27","author":"DD Gladman","year":"2000","unstructured":"Gladman DD, Goldsmith CH, Urowitz MB et al (2000) The Systemic Lupus International Collaborating Clinics\/American College of Rheumatology (SLICC\/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 27(2):373\u2013376","journal-title":"J Rheumatol"},{"issue":"5","key":"6125_CR21","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.jaad.2024.12.041","volume":"92","author":"Q Murat de Montai","year":"2025","unstructured":"Murat de Montai Q, Masseran C, Perray L et al (2025) Interferon-alpha biological activity is associated with disease activity and risk of flare in cutaneous lupus erythematosus: A monocentric study of 184 patients. J Am Acad Dermatol 92(5):1039\u20131048","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"6125_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J et al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83(1):15\u201329","journal-title":"Ann Rheum Dis"},{"key":"6125_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001007","author":"A Bao","year":"2023","unstructured":"Bao A, Petri MA, Fava A, Kang J (2023) Case series of Anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE. Lupus Sci Med. https:\/\/doi.org\/10.1136\/lupus-2023-001007","journal-title":"Lupus Sci Med"},{"issue":"3","key":"6125_CR24","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1093\/rheumatology\/kead553","volume":"63","author":"K Maeshima","year":"2024","unstructured":"Maeshima K, Abe T, Imada C, Ozaki T, Shibata H (2024) Anifrolumab for refractory lupus erythematosus panniculitis in systemic lupus erythematosus. Rheumatology (Oxford) 63(3):e115\u2013e7","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"6125_CR25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/03009742.2024.2306053","volume":"53","author":"Y Kobayashi","year":"2024","unstructured":"Kobayashi Y, Hanai S, Iwamoto T, Nakagomi D (2024) Refractory systemic lupus erythematosus with neuropsychiatric manifestations successfully treated with anifrolumab. Scand J Rheumatol 53(3):226\u2013228","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"6125_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/1346-8138.17027","volume":"51","author":"N Fushida","year":"2024","unstructured":"Fushida N, Horii M, Oishi K, Matsushita T (2024) Anifrolumab for systemic lupus erythematosus: a clinical study of Japanese patients in Kanazawa University Hospital. J Dermatol 51(4):607\u2013611","journal-title":"J Dermatol"},{"issue":"3","key":"6125_CR27","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/ijd.17022","volume":"63","author":"D Martin-Torregrosa","year":"2024","unstructured":"Martin-Torregrosa D, Mansilla-Polo M, Lasheras-Perez MA, Botella-Estrada R, Torres-Navarro I (2024) Refractory cutaneous lupus erythematosus successfully treated with anifrolumab: a case series. Int J Dermatol 63(3):368\u2013370","journal-title":"Int J Dermatol"},{"key":"6125_CR28","doi-asserted-by":"crossref","unstructured":"Viedma-Martinez M, Gallo-Pineda G, Jimenez-Gallo D, Linares-Barrios M (2025) [Translated article] Real-World Experience with Anifrolumab in Cutaneous Lupus Erythematosus: Data from a Spanish Tertiary Referral Center. Actas Dermosifiliogr","DOI":"10.1016\/j.ad.2025.05.013"},{"key":"6125_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jdcr.2024.11.014","volume":"55","author":"B Abdelmalik","year":"2025","unstructured":"Abdelmalik B, Svoboda S, Gurnani P, Motaparthi K (2025) Successful treatment of recalcitrant cutaneous lupus erythematosus with anifrolumab in patients without systemic lupus erythematosus. JAAD Case Rep 55:57\u201361","journal-title":"JAAD Case Rep"},{"key":"6125_CR30","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1016\/j.ard.2025.06.1892","volume":"84","author":"M Garbarino","year":"2025","unstructured":"Garbarino M, Bosch X, Corbella L et al (2025) ABS0821 ANIFROLUMAB IN CUTANEOUS AND SYSTEMIC LUPUS ERYTHEMATOSUS: A REAL-LIFE EXPERIENCE. Ann Rheum Dis 84:2234\u20132235","journal-title":"Ann Rheum Dis"},{"key":"6125_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14165683","author":"J Loricera","year":"2025","unstructured":"Loricera J, Bejerano C, Estebanez A et al (2025) Anifrolumab for nonsystemic cutaneous lupus erythematosus: clinical experience, immunologic insights, and review of the literature. J Clin Med. https:\/\/doi.org\/10.3390\/jcm14165683","journal-title":"J Clin Med"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06125-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06125-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06125-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:39:08Z","timestamp":1783525148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-026-06125-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["6125"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06125-0","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GAR has received honoraria and travel grants by the following entities: GSK, Astrazeneca, Amgen, Vifor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from all participants under the Panimmuno Research Protocol, conforming to the Declaration of Helsinki and approved by the San Raffaele Hospital Ethics Committee, Milan on the 8\n                      th\n                      of March 2018 (ref. 22\/INT\/2018). Written specific consent for publication was also obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No part of this report is copied or published elsewhere in whole or in part.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Originality statement"}}],"article-number":"89"}}